World Health Organization Raises Alert Over Acute Lack of Weight-Loss Medications

Less than a tenth of people that would benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it issues its first recommendations on the therapies.

With more than one billion individuals worldwide now classified as obese, it is advocating for increased and just availability to this class of drugs.

Based on forecasts, more than two billion could be living with obesity by 2030 without intervention.

"Our latest guidelines affirms that obesity is a lifelong illness that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to universal availability to the injections that can aid individuals in losing significant weight, says the agency.

GLP-1 Therapy Shortage

Despite the present best projected scenario, the supply of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, per the WHO.

The advice urges nations and manufacturers to widen access, via measures like patent sharing.

The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is scheduled to end in several nations in 2026.

The Way Weight-Loss Drugs Function

GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so people reduce food intake.

Individuals typically see weight reduction within a few weeks of beginning the weekly injections.

Research indicates patients may see weight return after a year of stopping the treatment, as their typical hunger return.

Being carrying excess weight elevates your risk for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity impacts people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.